Infections at record high as Omicron sweeps Israel, To cancel high COVID-risk designation of U.S.

Reading Time: 3 minutes

JERUSALEM, Jan 6 (Reuters) – Data from Israel on Thursday supported growing evidence worldwide that Omicron causes milder illness than previous variants of the coronavirus, even as the country grappled with a record number of daily infections.

Total hospitalisations on Wednesday stood at 363 patients, after the Health Ministry reported more than 16,000 new cases – a record high in Israel since the start of the pandemic – with a daily increase of 34 people falling severely ill.

During the height of Israel’s Delta variant wave, the record number of people infected topped 11,000, with the number of those falling severely ill increasing daily by around 100 and 1,300 people hospitalized.

“Our initial data, which is not yet entirely accurate, points to seven to eight people hospitalised for 1,000 infected, two of whom will fall severely ill or worse,” Sharon Alroy-Preis, the ministry’s head of public health, told Army Radio.

“This is a significant change from Delta which saw far more – at least 10 severely ill for every 1,000 infections,” she said.

Meanwhile, Israel is cancelling its designation of the United States and seven other countries as presenting high COVID-19 risk, Health Ministry director-general Nachman Ash said on Thursday.

The new measure will be in force as of midnight (2200 GMT).

A World Health Organization official said on Tuesday that more evidence was emerging of Omicron affecting the upper respiratory tract, causing milder symptoms than previous variants and resulting in a “decoupling” in some places between soaring case numbers and low death rates.

With infections rising fast, Israel’s testing centres have been buckling under the pressure, prompting health officials to prioritise risk groups and trust younger, vaccinated populations to test at home if exposed to a carrier.

Risk groups have also been green-lighted for a fourth dose of a COVID-19 vaccine and for Pfizer Inc and Merck & Co Inc’s antiviral COVID-19 medications.

A week into a fourth dose trial at a major Israeli hospital, researchers saw participants’ antibody levels increase five-fold.

But Gili Regev-Yochay, who is leading Sheba Medical Centre’s study, said that while the jump restored protection provided by a third dose, it was lower than what she had hoped for.

“I expect to see it continue rising, the peak of antibodies usually occurs two to four weeks in,” she told Army Radio.

(Editing by Jeffrey Heller; Editing by Emelia Sithole-Matarise)

Photo – People walk pass at a COVID-19 testing center outside the Tel Aviv Museum in Tel Aviv, Israel. EPA-EFE/ABIR SULTAN

Once you're here...

%d bloggers like this: